GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Net Margin %

Kazia Therapeutics (Kazia Therapeutics) Net Margin %

: 0.00% (As of Jun. 2023)
View and export this data going back to 1999. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Kazia Therapeutics's Net Income for the six months ended in Jun. 2023 was $-4.62 Mil. Kazia Therapeutics's Revenue for the six months ended in Jun. 2023 was $0.00 Mil. Therefore, Kazia Therapeutics's net margin for the quarter that ended in Jun. 2023 was 0.00%.

The historical rank and industry rank for Kazia Therapeutics's Net Margin % or its related term are showing as below:


KZIA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -163.32
* Ranked among companies with meaningful Net Margin % only.

Kazia Therapeutics Net Margin % Historical Data

The historical data trend for Kazia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -55.45 - -

Kazia Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.54 - - - -

Competitive Comparison

For the Biotechnology subindustry, Kazia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kazia Therapeutics Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's Net Margin % falls into.



Kazia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kazia Therapeutics's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin=Net Income (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-13.735/0
= %

Kazia Therapeutics's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin=Net Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-4.617/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kazia Therapeutics  (NAS:KZIA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Kazia Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kazia Therapeutics (Kazia Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Executives
Josiah T Austin director, 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204